update nirsevimab paper

Author: swo

_data/publications.yml

@@ -1,8 +1,9 @@
 - citation: '**SW Olesen**,  I Holmdahl, IR Ortega-Sanchez, M Biggerstaff,
   JM Jones, ML McMorrow, KE Fleming-Dutra. Projecting maximum potential
   demand for nirsevimab to protect eligible US infants and young children
-  against respiratory syncytial virus in the 2024/2025 season. *medRxiv* (2024).'
-  doi: 10.1101/2025.01.06.25319960
+  against respiratory syncytial virus in the 2024/2025 season. *Vaccine* (2025).'
+  doi: 10.1016/j.vaccine.2025.127109
+  pmid: 40209626
 - citation: 'NB Masters, I Holmdahl, PB Miller, CK Kumar, CM Herzog, PM
   DeJonge, S Gretsch, SE Oliver, M Patel, DE Sugarman, BB Bruce, BF Borah, **SW
   Olesen**. Real-time use of a dynamic model to measure the impact of public